March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
33 citations
,
April 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5α reductase inhibitors treat hair loss but may cause sexual side effects and risks.
May 2018 in “KU ScholarWorks (The University of Kansas)” Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
4 citations
,
September 2006 in “European Urology Supplements” Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
January 2002 in “映像情報メディア学会技術報告” Some prostate cancers have gene changes that may affect treatment with certain drugs.
2 citations
,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
19 citations
,
September 2016 in “Pharmacotherapy” Finasteride for hair loss increases risk of long-lasting sexual dysfunction.
January 2003 in “Zhonghua shiyan waike zazhi” Androgen, especially DHT, is crucial for erectile function in rats by affecting specific brain neurons.
86 citations
,
July 1993 in “Drugs” Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
February 2023 in “Sexual Medicine Reviews” 1 citations
,
January 2020 in “Seoul National University Open Repository (Seoul National University)” PDE3 inhibitor may help treat hair loss by promoting hair growth.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
May 2024 in “The journal of sexual medicine” Finasteride treatment may cause erectile dysfunction, but stopping it reverses these effects.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
2 citations
,
March 2021 in “Reproduction” Finasteride may affect male fertility by interfering with specific sperm signaling.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
September 2017 in “ics.org” 7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
14 citations
,
February 2011 in “Drug Metabolism and Disposition” Ketoconazole increases finasteride's effectiveness and lifespan in the body.
April 2023 in “Journal of Investigative Dermatology” Treprostinil, a drug, can delay wound healing in healthy cells but doesn't affect diabetic foot ulcer cells, suggesting further research could help understand its role in treating these ulcers.
August 2013 in “Circulation Research” Finasteride reduces heart enlargement and improves heart function.
June 2018 in “The Journal of Sexual Medicine” Finasteride does not negatively affect male reproductive function.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Dutasteride may protect the brain in early Parkinson's disease.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
January 2014 in “Reactions Weekly”